SAB Biotherapeutics
NASDAQ: SABSMiami Beach, US · Founded 2020 · Delaware corporation
Biotech
Founders & leadership
ES
Eddie SullivanExecutive Officer, Director
SR
Samuel ReichExecutive Officer, Director
RB
Russell BeyerExecutive Officer
JS
Jeffrey SpragensDirector
AM
Andrew MoinDirector
JS
Jay SkylerDirector
EL
Erick LuceraDirector
WP
William PolvinoDirector
KE
Katie ElliasDirector
DL
David LinkDirector
SG
Scott GibersonDirector
CH
Christine HamiltonDirector
Reported raises · per SEC filings
Form D private placements▶$175MraisedAug 2025 · 17 investors · BiotechnologyRule 506(b)
▶$175MraisedAug 2025 · 17 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Andrew MoinDirector
- Jay SkylerDirector
- Erick LuceraDirector
- Samuel ReichExecutive Officer, Director
- William PolvinoDirector
- Katie ElliasDirector
- Eddie SullivanExecutive Officer, Director
- Jeffrey SpragensDirector
- David LinkDirector
- Scott GibersonDirector
- Christine HamiltonDirector
- Offering amount
- $175M
- Amount sold
- $175M
- Sales commissions
- $10.5M
- Placement agents
- Oppenheimer & Co. Inc., Chardan Capital Markets, LLC, Leerink Partners LLC, UBS SECURITIES LLC
- First sale
- Jul 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$7.5MraisedOct 2023 · 13 investors · BiotechnologyRule 506(b)
▶$7.5MraisedOct 2023 · 13 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Russell BeyerExecutive Officer
- Erick LuceraDirector
- David Charles LinkDirector
- Samuel ReichExecutive Officer, Director
- Eddie J. SullivanExecutive Officer, Director
- William PolvinoDirector
- Christine HamiltonDirector
- Scott GibersonDirector
- Andrew MoinDirector
- Jeffrey G. SpragensDirector
- Offering amount
- $7.5M
- Amount sold
- $7.5M
- Sales commissions
- $450K
- Placement agents
- Chardan Capital Markets LLC
- First sale
- Oct 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Non-dilutive funding · 3 SBIR/STTR awards
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2019 | $1.4M |
| National Institutes of Health (NIH)National Institutes of Health | Phase I | 2019 | $199.6K |
| National Institutes of Health (NIH)National Institutes of Health | Phase II | 2016 | $1.4M |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.